|
Aug 8
|
Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report
|
|
Aug 5
|
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 5
|
Ocular Therapeutix: Q2 Earnings Snapshot
|
|
Aug 5
|
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
|
|
Jul 29
|
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
|
|
Jul 22
|
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
|
|
Jun 26
|
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
|
|
Jun 25
|
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
|
|
Jun 17
|
Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years
|
|
Jun 16
|
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
|
|
Mar 14
|
Why Ocular Therapeutix Was Bumping Higher This Week
|
|
Mar 11
|
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
|
|
Feb 24
|
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
|
|
Oct 9
|
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
|
|
Oct 8
|
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength
|
|
Sep 25
|
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
|
|
Jul 18
|
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 10
|
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
|
|
Jul 8
|
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 13
|
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
|